Abstract
Wastewater-based epidemiology (WBE) requires high-quality survey methods to determine the incidence of infections in catchment areas. In this study, the wastewater survey methods necessary for comprehending the incidence of infection by WBE are clarified. This clarification is based on the correlation with the number of confirmed coronavirus disease 2019 (COVID-19) cases, considering factors such as handling non-detect data, calculation method for representative values, analytical sensitivity, analytical reproducibility, sampling frequency, and survey duration. Data collected from 15 samples per week for two and a half years using a highly accurate analysis method were regarded as gold standard data, and the correlation between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA concentrations in wastewater and confirmed COVID-19 cases was analyzed by Monte Carlo simulation under the hypothetical situation where the quality of the wastewater survey method was reduced. Regarding data handling, it was appropriate to replace non-detect data with estimates based on distribution, and to use geometric means to calculate representative values. For the analysis of SARS-CoV-2 RNA in samples, using a highly sensitive and reproducible method (non-detect rates of < 40%; ≤ 0.4 standard deviation) and surveying at least three samples, preferably five samples, per week were considered desirable. Furthermore, conducting the survey over a period of time that included at least 50 weeks was necessary. A WBE that meets these survey criteria is sufficient for the determination of the COVID-19 infection incidence in the catchment area. Furthermore, WBE can offer additional insights into infection rates in the catchment area, such as the estimated 48% decrease in confirmed COVID-19 cases visiting a clinic following a COVID-19 legal reclassification in Japan.
Competing Interest Statement
MM: A relationship with NJS CO LTD that includes: consulting or advisory. HA: No competing interests to declare. RY: No competing interests to declare. ML: A relationship with AdvanSentinel that includes: funding grants and lecture honorarium. A relationship with Shimadzu Corporation that includes: funding grants. A relationship with Shionogi & Co. that includes: funding grants and lecture honorarium. Patent pending to Shionogi & Co., Ltd.
Funding Statement
This work was funded by “The Nippon Foundation - Osaka University Project for Infectious Disease Prevention,” the Japan Agency for Medical Research and Development (AMED) under grant number 24fk0108713h0001, and the Japan Science and Technology Agency (JST) through the JST-Mirai Program, under grant number JPMJMI22D1.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
We have included all the results produced in the present work in the manuscript. All data produced in the present study are available upon reasonable request to the authors.
